首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4202篇
  免费   24篇
  2018年   11篇
  2015年   31篇
  2014年   20篇
  2013年   1007篇
  2012年   19篇
  2011年   19篇
  2010年   16篇
  2009年   16篇
  2008年   22篇
  2007年   14篇
  2006年   80篇
  2005年   16篇
  2002年   11篇
  2001年   36篇
  2000年   37篇
  1999年   38篇
  1998年   60篇
  1997年   49篇
  1996年   201篇
  1995年   185篇
  1994年   179篇
  1993年   179篇
  1992年   175篇
  1991年   144篇
  1990年   137篇
  1989年   89篇
  1988年   102篇
  1987年   120篇
  1986年   86篇
  1985年   84篇
  1984年   97篇
  1983年   60篇
  1982年   78篇
  1981年   96篇
  1980年   98篇
  1979年   57篇
  1978年   76篇
  1977年   44篇
  1976年   45篇
  1975年   53篇
  1974年   22篇
  1973年   36篇
  1972年   49篇
  1971年   32篇
  1970年   19篇
  1969年   21篇
  1968年   15篇
  1966年   11篇
  1965年   11篇
  1963年   10篇
排序方式: 共有4226条查询结果,搜索用时 15 毫秒
191.
A literature search was conducted on studies of new drugs used with patients with schizophrenia reported by U.S. and non-U.S. researchers from 1966–1993, yielding 41 U.S., and a total of 24 other non-U.S. studies, among them 11 British studies. Results of the U.S. and non-U.S. studies were pooled separately and compared. Among several comparable conditions discussed, the lack of any data on suicides in the U.S. studies was observed. For a second statistical analysis of suicide rates ‘person-years’ were calculated to adjust for differing washout durations. The results obtained include findings that the percentage of patients relapsing in U.S. studies was slightly lower (37.9%) than in non-U.S. studies (46%); the percentage of patients dropping out in U.S. studies (10.5%) was higher than in non-U.S. studies (7.6%); known location of dropout patients in U.S. studies was 1.7%, compared to 2.6% in non-U.S. studies. The most interesting finding was that no suicides were reported in U.S. studies, compared to 0.6% of patients reported in British studies. Some U.S. studies used ‘challenge doses’, such as amphetamines or L-dopa; no non-U.S. studies reported their use. Compared to U.S. studies, those by non-U.S., and particularly British, researchers appeared to report adverse events in their studies. ‘Challenge’ drugs were not used; suicides were reported. It is estimated that the probability that no patients suicided who participated in the U.S. is small—one in 500.  相似文献   
192.
This paper addresses some critical issues in the applicability of quantitative performance measures (including bibliometric, economic, and co-occurrence measures) to the assessment of basic research. The strengths and weaknesses of metrics applied as research performance measures are examined. It is concluded that metrics have a useful role to play in the evaluation of research. Each metric employed, whether bibliometric, economic, co-occurrence, or others, brings a new dimension of potential insight to the complex problem of research assessment. However, when used in a stand-alone mode, metrics can be easily misinterpreted and result in misleading conclusions. Metrics should be an integral part of a more comprehensive approach to research evaluation, in which the leading role is assumed by expert peer review. Under this structure, the reviewers must be broadly constituted, so that the technical correctness of the research approaches being taken (doing the job right) can be evaluated by technical experts and the correctness of the research target (doing the right job) can be evaluated as well. This comprehensive approach insures quality in the implementation of existing research paradigms and allows the introduction of revolutionary new research paradigms as well. The views contained in this paper are solely those of the author and do not represent the views of the Department of the Navy. Ronald Kostoff received a Ph.D. from Princeton University, performed technical and economic research at Bell Laboratories, managed energy programs at U.S. Department of Energy, was Director of Technical Assessment at the Office of Naval Research for many years and presently manages the Navy’s In-House Laboratory Independent Research Program.  相似文献   
193.
194.
195.
Has suffering become an ugly word in the normalization debate? Are the disabled and their families forced into a Pollyanna 1 1 Pollyanna is the heroine in Eleanor Porter's book (1913), which has since been published in countless editions. Pollyanna received a pair of crutches when all she wanted was a doll. Because she didn't need to use her crutches, she was so happy that she played “being-happy” games for the rest of her life.
culture in order to be acknowledged and accepted in good company as the worthy disabled? This essay poses a controversial question: I would like to start a debate and ask whether normalization also has an unseen, ideological downside.  相似文献   
196.
COMMENTARY     
  相似文献   
197.
198.
199.
200.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号